Targeted therapy for lung cancer is a type of treatment that attacks cancer cells by zeroing in on specific genetic mutations or abnormal proteins driving the tumor’s growth. Unlike chemotherapy, which kills fast-dividing cells throughout the body, targeted drugs are designed to interfere with particular molecular signals that cancer cells depend on to survive and multiply. This makes them more precise, often more effective, and generally easier to tolerate than traditional chemo.
Most targeted therapies are used for non-small cell lung cancer (NSCLC), which accounts for roughly 85% of all lung cancers. Small cell lung cancer lacks the same kind of targetable mutations, so progress there has been much slower.
How Targeted Therapy Differs From Chemotherapy
Chemotherapy works broadly. It poisons cells that divide quickly, which includes cancer cells but also healthy cells in your hair follicles, gut lining, and bone marrow. That’s why chemo causes hair loss, nausea, and weakened immunity. Targeted therapy, by contrast, homes in on a specific molecular flaw in the tumor. If a cancer cell has a particular genetic mutation acting like a stuck “on” switch for growth, a targeted drug can block that switch.
The result is that cancer cells are hit hard while normal cells are largely spared. In practice, many patients on targeted therapy can maintain a more normal daily life compared to those on chemotherapy. Some targeted drugs are taken as daily pills at home rather than requiring infusion visits. Doctors sometimes combine targeted drugs with chemotherapy when the combination offers better disease control than either approach alone.
Biomarker Testing: The First Step
Targeted therapy only works if your tumor carries a mutation the drug is designed to block. That’s why biomarker testing (also called molecular profiling) is essential before treatment begins. Doctors typically analyze a tissue sample from a biopsy using techniques like next-generation sequencing, which can scan for many mutations at once.
When tumor tissue is hard to reach or the biopsy sample is too small for full testing, a liquid biopsy can fill the gap. This involves a simple blood draw that detects fragments of tumor DNA circulating in the bloodstream. Liquid biopsy is less invasive and can capture genetic information from multiple tumor sites at once, giving a broader picture of the cancer’s mutations. However, it has a sensitivity of only about 70% in advanced disease, so a negative liquid biopsy result should be followed up with a tissue biopsy when possible. Liquid biopsy also can’t determine the cancer’s specific cell type or certain protein markers that influence treatment decisions, so it complements rather than replaces traditional biopsy.
The Most Common Targetable Mutations
Not every lung cancer has a mutation that current drugs can target, but a significant number do. In NSCLC, the most frequently found actionable mutations and their approximate prevalence are:
- KRAS (especially the G12C variant): The most common, found in roughly 37 to 42% of NSCLC cases. About 37 to 40% of those KRAS mutations are the specific G12C type that newer drugs can target, translating to around 14 to 17% of all NSCLC patients.
- EGFR: Present in about 20% of NSCLC cases. This is the most well-established target, with several generations of drugs available.
- MET exon 14 skipping: Found in roughly 2 to 5% of cases.
- ALK fusions: About 1 to 2.5% of cases.
- BRAF V600E: Around 0.4 to 3.4%.
- RET fusions: About 0.5 to 0.7%.
- ROS1 fusions: Around 0.4 to 0.7%.
- NTRK fusions: Rare, under 1%.
Even mutations that affect only a small percentage of patients represent real treatment opportunities. Because lung cancer is so common, even a 1% prevalence translates to thousands of people each year who could benefit from a matched targeted drug.
EGFR-Targeted Treatments
EGFR mutations were the first major targetable discovery in lung cancer, and the drug landscape here is the most mature. The current standard for most EGFR-mutated NSCLC is a third-generation inhibitor called osimertinib, which blocks the most common EGFR mutations and penetrates into the brain well enough to help control tumors that have spread there. Updated 2025 guidelines now recommend osimertinib as a consolidation option even for patients with unresectable stage II or III disease whose tumors haven’t progressed after initial chemoradiation.
For patients whose tumors carry a less common EGFR mutation (exon 20 insertions), different drugs are needed. In 2024, the FDA approved a combination approach pairing a newer antibody-based drug with chemotherapy as a first-line treatment specifically for these exon 20 insertion mutations.
ALK and ROS1 Rearrangements
ALK and ROS1 fusions are less common but highly treatable. Multiple generations of drugs exist for ALK-positive lung cancer, and results are often striking. Based on the ALINA trial, 2025 guidelines now recommend alectinib as an adjuvant (post-surgery) treatment for ALK-positive disease, a significant expansion of when targeted therapy can be used.
For ROS1-rearranged tumors, early drugs showed response rates of about 72%, with disease held in check for a median of roughly 19 months. Newer agents have pushed response rates even higher. In one study of treatment-naive patients, an alternative drug achieved an 86% response rate with a median of 19 months before the disease progressed. Several of these drugs also cross into the brain effectively, which matters because lung cancer commonly spreads there. In one trial, 80% of patients with brain metastases from ROS1-positive tumors saw their brain tumors shrink.
KRAS G12C: A Once “Undruggable” Target
For decades, the KRAS protein was considered impossible to target with drugs. That changed in 2021 with the first approved KRAS G12C inhibitor, followed by a second drug that received accelerated FDA approval in December 2022. These are currently approved for patients whose KRAS G12C-mutated NSCLC has progressed after at least one prior treatment. Companion diagnostic tests, available through both tissue and blood-based platforms, are approved alongside these drugs to confirm the mutation.
While KRAS G12C inhibitors haven’t yet matched the dramatic response rates seen with EGFR or ALK drugs, they opened a door for the largest single group of mutation-carrying lung cancer patients, and newer combinations are being actively tested to improve outcomes.
Side Effects of Targeted Therapy
Targeted therapies are generally better tolerated than chemotherapy, but they aren’t side-effect free. The specific side effects depend on which molecular pathway the drug blocks. The most common issues include skin problems (rash, itching, dry skin), diarrhea, and potential damage to the liver, kidneys, or thyroid gland.
Skin rash is particularly common with EGFR-targeted drugs. It can range from mild to quite bothersome, sometimes requiring dose adjustments or skin-focused treatments. Diarrhea is another frequent side effect across several drug classes. Doctors typically monitor liver and thyroid function with regular blood tests during treatment. Most side effects are manageable and reversible, but they do require ongoing communication with your care team so adjustments can be made early.
Why Targeted Therapy Eventually Stops Working
One of the most frustrating aspects of targeted therapy is that cancers almost always develop resistance over time. The tumor cells mutate further, finding workarounds to bypass the drug’s blockade. A mechanism of resistance can be identified in roughly 60 to 70% of cases that progress on treatment.
The most well-understood example is the T790M mutation, which appears in about 50% of patients whose EGFR-mutated tumors stop responding to earlier-generation drugs. This specific resistance mutation is the reason third-generation EGFR inhibitors were developed. Other resistance mechanisms include the tumor activating entirely different growth pathways to sidestep the blocked one, or even transforming into a different cell type altogether.
When resistance develops, doctors often perform another biopsy (tissue or liquid) to identify the new mutation driving growth. This information can guide the next treatment choice, whether that’s a different targeted drug, immunotherapy, chemotherapy, or a combination. The timeline varies widely: some patients respond to a targeted drug for years, while others see resistance emerge within months.
Targeted Therapy and Small Cell Lung Cancer
Nearly all of the targeted therapy advances apply to non-small cell lung cancer. Small cell lung cancer (SCLC) is biologically different, with fewer of the clearly targetable mutations that make precision drugs possible. Antiangiogenic drugs that worked in NSCLC have failed to improve survival in SCLC, underscoring just how distinct these cancers are at the molecular level. Research into SCLC-specific targets is ongoing, but for now, chemotherapy and immunotherapy remain the mainstays for that disease.